Juno Therapeutics
NEWS
Juno Therapeutics was acquired by Bristol-Myers Squibb in 2019.
Here’s a look at who shook things up in the world of pharma and biotech this week.
China’s Hillhouse Capital Group, an equity investment firm, has a new fund, Hillhouse Fund IV, with $10.6 billion ready to invest.
According to BioPharmCatalyst, there have been (or soon will be) 58 biopharma initial public offerings (IPOs) in 2018, and there’s still more than three months to go.
Without a doubt China has become one of the most important markets for pharma companies, given the vast patient population and the rising cancer rates. And it seems that western pharmaceutical companies are making greater inroads there.
It’s not easy to predict trends in drugs, especially with breakthroughs in immunology and genetic engineering often causing dramatic changes in how biopharma companies approach new drugs.
GSK’s Hal Barron, former Juno Chief Executive Officer and others take on or transition into new roles. Let’s take a look at some of those!
Because of the potential for significant side effects of CAR-T therapies, the FDA requires Risk Evaluation and Mitigation Strategies (REMS) programs. The Bezos Family Immunotherapy Clinic at the Seattle Cancer Care Alliance is one of those approved sites.
It’s hard to believe 2018 is half over. There have been plenty of interesting and important stories in the biopharma space this year. Here’s a look at our top 10 stories so far, counting down from 10 to the number one story.
So far during the first six months of the year, more than $100 billion has been spent on a myriad of acquisitions across the pharma and biotech industries.
JOBS
IN THE PRESS
